Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> MutationBella Kaufman, Susan M. Domchek, Ronnie Shapira‐Frommer et al.|Journal of Clinical Oncology|2014Cited by 1.7k
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M. Domchek, Bella Kaufman, Carol Aghajanian et al.|Gynecologic Oncology|2015Cited by 300
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for CancerAmir Massarweh, Salomon M. Stemmer, Jihad Bishara et al.|JAMA Oncology|2021Cited by 291
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung CancerDaniel A. Goldstein, Alona Zer, Noa Gordon et al.|JNCI Journal of the National Cancer Institute|2017Cited by 102
Therapeutic Efficacy of Injectable Hydrogel Systems in Mice Tumor ModelsDavid R. Elmaleh, Salomon M. Stemmer|Preprints.org|2025Cited by 0